Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.
about
Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activationGemifloxacin, a fluoroquinolone antimicrobial drug, inhibits migration and invasion of human colon cancer cellsLomefloxacin Induces Oxidative Stress and Apoptosis in COLO829 Melanoma Cells.
P2860
Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@en
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@nl
type
label
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@en
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@nl
prefLabel
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@en
Ciprofloxacin is a potential t ...... reatment of NSCLC.
@nl
P2093
P2860
P356
P1476
Ciprofloxacin is a potential t ...... treatment of NSCLC
@en
P2093
Jakub Marcin Nowak
Jakub Tworkiewicz
Jan Adamowicz
Joanna Olkowska
Natalia Gurtowska
Robert Dębski
Tomasz Drewa
P2860
P304
P356
10.3892/IJO.2012.1653
P577
2012-10-04T00:00:00Z